Cargando…

Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience

Background: The safety impact of radiotherapy (RT) timing relative to immune checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval 2) of ICI use is associated with toxicities compared to RT out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tjong, Michael C., Ragulojan, Malavan, Poon, Ian, Louie, Alexander V., Cheng, Susanna Y., Doherty, Mark, Zhang, Liying, Ung, Yee, Cheung, Patrick, Cheema, Parneet K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775081/ https://www.ncbi.nlm.nih.gov/pubmed/35049695 http://dx.doi.org/10.3390/curroncol29010021

Ejemplares similares

Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review
por: Tjong, Michael C., et al.
Publicado: (2020)

Unanticipated Radiation Replanning for Stage III Non-small Cell Lung Cancer
por: Mushonga, Melinda, et al.
Publicado: (2023)

The Role of a Longitudinal, Multidisciplinary Clinic in Building a Unique Research Collaborative
por: Gonzales, Alexandria A., et al.
Publicado: (2022)

Current Management and Progress in Radiotherapy for Small Cell Lung Cancer
por: Tjong, Michael C., et al.
Publicado: (2020)

Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience
por: Glicksman, Rachel M, et al.
Publicado: (2020)

The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
por: Perdrizet, Kirstin, et al.
Publicado: (2021)

Checkpoint inhibitor-induced sarcoid choroidal granulomas
por: Ung, Cindy, et al.
Publicado: (2020)

Radiotherapy and checkpoint inhibitors: a winning new combination?
por: Ko, Eric C., et al.
Publicado: (2018)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
por: Porte, Judith, et al.
Publicado: (2022)

Detection of solid and subsolid pulmonary nodules with lung MRI: performance of UTE, T1 gradient-echo, and single-shot T2 fast spin echo
por: Sanchez, Felipe, et al.
Publicado: (2023)

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy
por: Oikonomou, Anastasia, et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
por: Liu, Zijing, et al.
Publicado: (2023)

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
por: Cheema, Parneet K., et al.
Publicado: (2022)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis
por: Li, Xin, et al.
Publicado: (2017)

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
por: Jungles, Kassidy M., et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study
por: Baydoun, A., et al.
Publicado: (2021)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research
por: Cheung, Yee-Ming M, et al.
Publicado: (2023)

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors
por: Poon, Darren MC, et al.
Publicado: (2023)

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021)

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2022)

Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non‐small cell lung cancer patients with recurrence or metastasis: A systematic review and meta‐analysis
por: Zeng, Yichun, et al.
Publicado: (2023)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy
por: Liao, Xiu-Yong, et al.
Publicado: (2019)

Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
por: Öjlert, Åsa Kristina, et al.
Publicado: (2021)

Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy
por: Bajpai, Jyoti, et al.
Publicado: (2021)

Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan
por: Hsu, Jason C., et al.
Publicado: (2018)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7odlt1livin8thfik068cdv9hn